title: Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
authors.forename: S S
authors.initials: SS
authors.lastname: Ramalingam
authors.forename: K
authors.initials: K
authors.lastname: O'Byrne
authors.forename: M
authors.initials: M
authors.lastname: Boyer
authors.forename: T
authors.initials: T
authors.lastname: Mok
authors.forename: P A
authors.initials: PA
authors.lastname: Jänne
authors.forename: H
authors.initials: H
authors.lastname: Zhang
authors.forename: J
authors.initials: J
authors.lastname: Liang
authors.forename: I
authors.initials: I
authors.lastname: Taylor
authors.forename: E I
authors.initials: EI
authors.lastname: Sbar
authors.forename: L
authors.initials: L
authors.lastname: Paz-Ares